Status:

COMPLETED

Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV

Lead Sponsor:

Germans Trias i Pujol Hospital

Collaborating Sponsors:

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Conditions:

HIV Infections

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to compare the early virological response (EVR = undetectable \[ribonucleic acid-hepatitis C virus\] RNA-HCV or a reduction of \> 2 log10) of patients with chronic hepatit...

Detailed Description

This study seeks to ascertain whether treatment with higher doses of PEGASYS (270 µg/week) and ribavirin (1600 mg/day) for the first four weeks achieves the plasma concentrations of the product in the...

Eligibility Criteria

Inclusion

  • Serological evidence of chronic hepatitis C infection in an anti-HCV antibody test
  • Detectable RNA-HCV plasma level genotype 1 and 4
  • ALT serum activity above the upper limit of normality
  • Chronic liver disease consistent with chronic hepatitis C infection in a biopsy obtained during the two years prior to inclusion in the study
  • Serological evidence of HIV-1 infection, diagnosed by Enzyme-Linked Immunosorbent Assay (ELISA) and confirmed by Western-blot.
  • Patients with CD4 cell count \> 200 /µl
  • Stable status in HIV-1 infection, in the investigator's opinion, in other words, patients that are not expected to progress during the study.
  • Patients treated with stable anti-retroviral therapy (HAART), which does not include nucleoside analogues, for at least 6 weeks before the baseline assessment
  • Patients that do not receive HAART therapy
  • Negative pregnancy test in urine or blood

Exclusion

  • Women currently pregnant or in the lactation period.
  • Patients whose companion is pregnant.
  • Therapy with interferon (IFN) or ribavirin at any previous time.
  • Patients with cirrhosis in the hepatic biopsy.
  • Documented suspicion by ultrasound of hepatocarcinoma.

Key Trial Info

Start Date :

October 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2009

Estimated Enrollment :

74 Patients enrolled

Trial Details

Trial ID

NCT00356486

Start Date

October 1 2005

End Date

March 1 2009

Last Update

December 4 2019

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Hospital Germans Trias i Pujol, Badalona

Badalona, Barcelona, Spain, 08916

2

Consorci Sanitari de Terrassa

Terrassa, Barcelona, Spain, 08221

3

Hospital General de Vic

Vic, Barcelona, Spain, 08500

4

Hospital de Donostia

San Sebastián, Donostia, Spain, 20012